Expressing support for the designation of the week of May 3, 2026, through May 9, 2026, as "Tardive Dyskinesia Awareness Week".
- Bill Number
- H.Res. 1265
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-05-07: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-05-21T14:27:16Z
AI-Generated Summary
Purpose
This House Resolution (H. Res. 1265) expresses the U.S. House of Representatives' support for designating the week of May 3 through May 9, 2026, as Tardive Dyskinesia Awareness Week. It aims to raise public and medical awareness about tardive dyskinesia (TD), a movement disorder caused by prolonged use of certain medications like antipsychotics (used for mental illnesses such as schizophrenia or bipolar disorder) and antiemetics (used for nausea or stomach issues).
Key Provisions
- Supports the designation of the specified week as "Tardive Dyskinesia Awareness Week."
- Encourages all individuals in the United States to learn more about TD, its symptoms (uncontrollable, repetitive movements of the face, body, arms, legs, fingers, or toes), risks, monitoring, and treatments.
- Highlights background facts:
- Affects an estimated 600,000 people in the U.S., with ~60% undiagnosed.
- Impacts physical, social, and emotional well-being, even in mild cases.
- Regular screening recommended by the American Psychiatric Association.
- FDA-approved treatments available for adults.
Significant Changes to Existing Law
- None. This is a non-binding resolution that does not create new laws, mandate actions, or allocate funds.
Potential Impacts
- Citizens: Increases awareness of TD symptoms and the need for monitoring, potentially leading to earlier diagnosis and treatment for those on dopamine-blocking medications (e.g., for mental health or gastrointestinal issues).
- Government agencies: No direct effects; referred to the House Committee on Energy and Commerce for consideration.
- International relations: None.
- Overall, symbolic impact focused on education rather than enforcement.
Main Stakeholders Affected
- Patients: Individuals with serious mental illnesses (e.g., schizophrenia, bipolar disorder) or gastrointestinal conditions treated with relevant medications.
- Healthcare providers: Doctors and psychiatrists responsible for monitoring and screening for TD.
- Medical and advocacy communities: Groups like the American Psychiatric Association benefiting from heightened awareness.
- Sponsors: Representatives Darren Peters, Gus Bilirakis, Markwayne Mullin, and Aaron Bean (bipartisan support).
Notable Legal, Constitutional, or Political Implications
- Legal/Constitutional: None significant; resolutions like this are expressions of opinion by the House and have no force of law.
- Political: Demonstrates congressional interest in mental health and medication side effects; bipartisan sponsorship signals broad support without controversy. Referred to committee, unlikely to bind future actions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Peters, Scott H. [D-CA-50]
Cosponsors (3)
Rep. Bilirakis, Gus M. [R-FL-12], Rep. Mullin, Kevin [D-CA-15], Rep. Bean, Aaron [R-FL-4]
Recent Actions
- 2026-05-07: Referred to the House Committee on Energy and Commerce.
- 2026-05-07: Submitted in House
Bill Versions
- Expressing support for the designation of the week of May 3, 2026, through May 9, 2026, as "Tardive Dyskinesia Awareness Week". — issued 2026-05-07 — PDF (2 pages)